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Background: Steroid-induced osteonecrosis of the femoral head (steroid-induced ONFH) presents great challenges
due to the various effects of steroids on multi-system pathways involved into osteoblast differentiation, osteoblast
and osteoclast apoptosis, lipid metabolism, calcium metabolism and coagulation. As one of the most frequently
used herbs in Traditional Chinese Medicine formulas that are prescribed for the regulation of bone and mineral
metabolism, the therapeutic effects of Achyranthes bidentata on steroid-induced ONFH remain unclear. Thus, the
aim of the current study was to verify whether Achyranthes bidentata extract (ABE) can be used to prevent
steroid-induced ONFH and to investigate its underlying pharmacological mechanisms.
Methods: Steroid-induced ONFH rat models were established to evaluate the effects of ABE treatment on
osteonecrotic changes and repair processes. Microfocal computed tomography (Micro-CT) was performed to assess
the effects of ABE treatment on bone mass, microstructure, and vascularization. Then, the effects of ABE treatment
on osteoclast differentiation and bone formation were also evaluated in vivo and in vitro. In addition, receptor
activator of nuclear factor kappa B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) expression in sera,
femoral heads and bone marrow-derived mesenchymal stem cells (BMSCs) were detected at both protein and
mRNA levels.
Results: The ratio of empty lacuna, adipose tissue area, and adipocyte perimeter in the bone marrow were
markedly lower in the ABE treatment groups than in the model group. Micro-CT evaluation indicated that ABE
treatment could improve the microstructure of the trabecular bone, increase bone mineral density and promote
vascularization in steroid-induced ONFH rats. Moreover, ABE treatment inhibited osteoclast differentiation and
activated bone formation markers. Interestingly, OPG downregulation, RANK and RANKL upregulation, and an
increased ratio of RANKL to OPG in sera and necrotic femoral head could be reversed by ABE treatment, which also
effectively inhibited RANKL-induced osteoclast differentiation and regulated RANKL and OPG expression of in vitro.
Conclusion: ABE may prevent steroid-induced ONFH and alleviate steroid-induced bone deterioration by regulating
the RANKL/RANK/OPG signaling pathway.
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Steroid-induced osteonecrosis of the femoral head (ster-
oid-induced ONFH) is a serious complication in patients
who have received steroids for the treatment of various
diseases, including nephrotic syndrome, renal transplant-
ation, and systemic lupus erythematosus [1]. As a degen-
erative bone disease, it leads to the collapse of the femoral
head, which subsequently destroys the hip joint and influ-
ences the patient’s activities [2]. Owing to the various ef-
fects of steroids on multi-system pathways involved in
osteoblast differentiation, osteoblast and osteoclast apop-
tosis, lipid metabolism, calcium metabolism, and coagula-
tion, it has been challenging to fully elucidate the
pathogenesis and etiology of steroid-induced ONFH [3].
According to recent studies, ONFH is caused by the im-
pairment of bone cell survival and bone formation, as well
as the promotion of osteoclastic resorption and adipocytic
differentiation in bone microenvironments [4]. Current
treatment for steroid-induced ONFH focuses on prevent-
ing irreversible complications, such as biomechanical col-
lapse of the femoral head and osteoarthritis of the hip
joint. However, these treatments were limited in their abil-
ity to enhance bone repair and to prevent collapse of the
articular surface and hip arthroplasty [5]. Therefore, novel
and efficient agents for the treatment of this disease are
needed.
An increasing number of plant-based therapies derived
from traditional Chinese medicine (TCM) have been
shown to be effective in the treatment of bone injuries
and bone-related diseases via strengthening of bones and
muscles and easing joints [6]. Achyranthes bidentata, an
important medicinal plant of the Amaranthaceae family
that has been listed in the Chinese Pharmacopoeia [5], is
one of the most frequently used herbs in formulas that are
prescribed for the regulation of bone and mineral metab-
olism [7]. Achyranthes bidentata is rich in active phyto-
chemical compounds including oleanolic acid glycosides,
saponins, ecdysterone, ketosteroids, and flavonoids, and
produces effects that include invigoration of the liver and
kidneys, strengthening of the muscles and bones, promo-
tion of blood flow, removal of blood stasis, and increase in
longevity [8-10]. Five new oleanolic acid glycosides from
Achyranthes bidentata have been reported to inhibit the
formation of osteoclasts [11]. Of these compounds, ecdys-
terone and daucosterol markedly stimulate proliferation of
osteoblast-like UMR106 cells, and ecdysterone increases
osteoblastic activity [12]. The flavonoid quercetin, also
found in Achyranthes bidentata decreases osteoclastic dif-
ferentiation [13]. Based on these results, we hypothesize
that Achyranthes bidentata may produce a therapeutic ef-
fect on steroid-induced ONFH. Thus, the aim of the
current study was to verify whether Achyranthes bidentata
extract (ABE) prevents steroid-induced ONFH and to in-
vestigate its underlying pharmacological mechanisms.Materials and methods
This study was approved by the Research Ethics Committee
of the Institute of Chinese Materia Medica, China Academy
of Chinese Medical Sciences, Beijing, China. All animals
were treated in accordance with the guidelines and regula-
tions for the use and care of animals at the Center for La-
boratory Animal Care, China Academy of Chinese Medical
Sciences.
ABE preparation and analysis
Achyranthes bidentata was purchased from Beijing Medi-
cinal Herbs Co. Ltd. (Beijing, China), and identified and
authenticated by Professor Zhenli Liu at the Institute of
Basic Theory of Traditional Chinese Medicine, China
Academy of Chinese Medical Sciences. Achyranthes
bidentata (500 g) was pulverized to a fine powder and
boiled twice with 4 L of 80% ethanol for 1 h under reflux.
The ethanol extracts were collected and filtered. The fil-
trates were concentrated under reduced pressure at 50°C
to 500 mL by a concentration of 2 g/mL.
An HPLC method was developed for the quantification
of β-ecdysone in the extract. A Waters 2695 instrument
equipped with a UV detector at 250 nm was used with a
stationary phase of Agilent Zorbax SB-C18 (4.6 × 150 mm,
5 μm) at 30°C and a mobile phase of acetonitrile:0.1%
methanoic acid (15:85) (Fisher, Waltham, Massachusetts,
USA) running at 1 mL/min. The ABE used in this trial
contained 0.0425% β-ecdysone (Figure 1).
Cells and culture system
Bone marrow cells were obtained from the long bones of 4-
6-week-old C57 mice (Peking university health science cen-
ter, Cat No. SCXK: 2011–0012). Bone marrow cells cultured
in the presence of M-CSF (20 ng/ml, PeproTech, Inc., Rocky
Hill, NJ, USA) for 3 days to generate bone marrow derived
macrophages (BMMs).
Bone marrow cells were obtained from the long bones of
4-6-week-old C57 mice (Peking university health science
center, Cat No. SCXK: 2011–0012) by flushing with α-
minimum essential medium containing antibiotics (Sigma,
St. Louis, MO, USA), and further red blood cells (RBC)
were removed with RBC lysis buffer (Sigma, St. Louis, MO,
USA). The cells were plated on 90-mm culture dishes
(Corning, NY, U.S.A.) and incubated for 3 days in a-MEM
containing 15% FCS and antibiotics. Adherent cells were
used as bone marrow mesenchymal stem cells (BMSCs).
Animals
One hundred and five 12-week-old male Wistar rats (Cat
No. SCXK-(Jun) 2007–004) weighting 300–320 g were ob-
tained from the Experimental Animal Centre of the Acad-
emy of Military Medical Sciences (Beijing, China). All rats
were maintained in a room equipped with an air-filtering
system, and the cages and water were sterilized.
Figure 1 Chromatograms for β-ecdysone (A) and 80% ethanol extract of Achyranthes bidentata (B).
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After 1 week of feeding adaptation, the animals were
weighed and randomly divided into 5 groups: control
(n =20), model (rats with steroid-induced ONFH, n =25),
ABE 10 g/kg (rats with steroid-induced ONFH treated
with 10 g/kg ABE, n =20), ABE 15 g/kg (rats with steroid-
induced ONFH treated with 15 g/kg ABE, n =20), and
ABE 22.5 g/kg (rats with steroid-induced ONFH treated
with 22.5 g/kg ABE, n =20). The steroid-induced ONFH
rat model was implemented according to previous studies
[14,15]. Briefly, methylprednisolone acetate (MPSL, Pfizer
Manufacturing, Puurs, Belgium) (21 mg/kg) was injected
subcutaneously for 6 weeks to induce osteonecrosis. One
hour after the MPSL injection, rats in the ABE 10 g/kg,
ABE 15 g/kg, and ABE 22.5 g/kg groups, received ABE
dissolved in distilled water by oral gavage at 10 g/kg/d,
15 g/kg/d and 22.5 g/kg/d respectively for 6 weeks. In the
control and model groups, the rats received no treatment.
The animals were fed a standard diet and allowed free
activity.
Tissue sample preparation
Rats from each group were killed 6 weeks after the methyl-
prednisolone injection. The rats were anaesthetized with an
intravenous injection of trichloroacetaldehyde hydrate
(0.3 mL/kg, Sinopharm Chemical Reagent Co., Ltd, China)
and were then killed by exsanguination via an aortectomy.
Bilateral femora were obtained at the time of death and the
left sides were fixed for 3 days in 4% paraformaldehyde(pH 7.4) to prepare for the microfocal computed tomog-
raphy (Micro-CT) and light microscopy examinations.
After micro-CT scanning, the bone samples were decalci-
fied with ethylenediaminetetraacetic acid (EDTA, 10%,
pH 7.4) for 28 days. Samples were sectioned along the cor-
onal plane for the proximal one-third and cut along the
axial plane in the distal part (condyle). Finally, the speci-
mens were embedded in paraffin, cut into 5 mm sections,
and stained with hematoxylin and eosin. The right sides
were stored at −80°C for western blots and real-time PCR.
Evaluation of steroid-induced ONFH
Osteonecrotic changes and repair processes in steroid-
treated rats were observed by histopathological examin-
ation using a light microscope 6 weeks after the MPSL
injection. The slides were evaluated in a blinded fashion by
3 independent observers. The evaluation criteria for osteo-
necrosis were based on the report of Yamamoto et al. [16].
Osteonecrosis was judged to be present when there was ne-
crosis of medullary hematopoietic cells or fat cells, empty
lacunae, or condensed nuclei in osteocytes. The ratio of
empty lacunae (empty lacunae/the total number of osteo-
cytes) was calculated for each femoral head using a coronal
section taken at the maximal femoral width. Image Pro 6.0
was used for this calculation.
Micro-CT
A Micro-CT (μCT, GE Healthcare Biosciences, Piscataway,
NJ, USA) was used to detect changes in the excised femoral
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ters were calculated: bone volume (BV), bone surface (BS),
trabecular bone pattern factor (Tb.Pf), structure model
index (SMI), trabecular thickness (Tb.Th), trabecular num-
ber (Tb.N), trabecular separation (Tb.Sp), and bone mineral
density (BMD).
Quantification and three-dimensional visualization of
vessel networks
Femoral head blood vascularization in steroid-treated rats
was measured using Micro-CT-based micro-angiography
6 weeks after methylprednisolone injection according to
previously reported methods [17,18]. Briefly, rats from
each group were anaesthetized as described above and the
thoracic and abdomen cavities were opened. A hypoder-
mic needle with disposable infusion device was inserted in
the ventriculus sinister with ligation of that proximal to
the aorta ascendens. The vasculature was flushed with
500 ml heparinized saline (50 U/ml) at 37°C via a dispos-
able infusion device. After flushing, 500 ml 4% parafor-
maldehyde solution was pumped into the vasculature to
fix the tissues and blood vessels. The vasculature was then
injected with Microfil based on the manufacturer’s proto-
col (Microfil MV-122, Flow Tech, Carver, MA, USA).
Animals were then stored overnight at 4°C to ensure
polymerization of the contrast agent before microangio-
graphy. Bilateral femoral samples were harvested and fixed
in 4% paraformaldehyde and 10% EDTA. After perfusion
and decalcification, the femoral shaft was fixed in a poly-
methylmethacrylate sample tube with its long axis perpen-
dicular to the bottom of the tube in preparation for
Micro-CT scanning. The scan was perpendicular to the
shaft and was initiated from a reference line 10 mm away
from the bottom with a scan length of 10 mm.
Hematological examination
To detect the hyperlipidemia-improving effects of prava-
statin, blood samples were collected from the abdominal
aorta 6 weeks after methylprednisolone administration.
The serum levels of total cholesterol (TC), triglycerides
(TG), low-density lipoprotein (LDL), high-density lipopro-
tein (HDL), apolipoprotein A1 (ApoA1), and apolipopro-
tein B (ApoB) were determined.
Analysis of Tartrate-resistant acid phosphatase (TRAP),
bone-specific alkaline phosphatase (BAP), receptor
activator of nuclear factor kappa B (RANK), RANK ligand
(RANKL), and osteoprotegerin (OPG) levels in serum and
BMSCs
Serum was separated from 5 mL blood samples. BMSCs
were cultured for 3 days in the presence of 15% FCS with or
without ABE (0.16, 0.8, 4 μg/ml, respectively) in 96 well cul-
ture plate. Supernatants were obtained and stored at −80°C
until use. TRAP, BAP, RANK, RANKL, and OPG weremeasured using enzyme linked immunosorbent assay
(ELISA) kits (for TRAP: Kamiya Biomedical Company,
Seattle, WA; for BAP: Quidel Corp., San Diego, CA; for
RANK, RANKL, and OPG: R&D Systems, Minneapolis,
MN) that were specific for the rat. The concentration of the
reaction product was determined from a standard curve.
Western blot analysis
The protein expression levels of RANK, RANKL, and
OPG in the femoral head tissues obtained from rats in
different groups were detected by western blot analysis.
The western blot protocol and semiquantitative analysis
were carried out following the protocol of our previous
study [19]. The following antibodies were used: RANK
antibody (rabbit antibody, dilution 1:50, Cell Signaling
Technology, Inc., Danvers, MA, USA), RANKL antibody
(rabbit antibody, dilution 1:100, Millipore Corporation,
Billerica, MA, USA), OPG antibody (rabbit antibody, di-
lution 1:100, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), and GAPDH antibody (internal control,
rabbit polyclonal antibody, dilution 1:200, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA).
RNA isolation and real-time PCR
The expression of RANK, RANKL, and OPG in the femoral
head tissues was analyzed by real-time PCR. A small cube of
trabecular bone (proximal femur) was homogenized, and
the total RNA was isolated with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). The extracted RNA was dissolved in
RNAse-free distilled water. The quality and quantity of the
RNA samples were determined by spectrophotometry, with
the ratios of absorbance at 260 nm and 280 nm ranging
from 1.8 to 2.0. Next, 3 mg of total RNA was reverse-
transcribed into cDNA using a High-Capacity cDNA Kit
(Takara Bio Inc., Tokyo, Japan) according to the manufac-
turer’s instructions. The specific transcripts were quantified
by quantitative real-time PCR using the QuantiTect SYBR
Green PCR Kit (Takara Bio Inc., Tokyo, Japan) and analyzed
with an ABI 7500 real-time PCR system (Applied Biosys-
tems, Foster City, CA, USA). Gene-specific primers used for
RANK, RANKL, OPG and GAPDH were listed in Table 1.
The mRNA levels of RANK, RANKL, and OPG were nor-
malized to GAPDH mRNA levels. PCR was performed as
40 cycles at 94°C for 15 s, 55°C for 30 s, and 72°C for 30 s.
The relative mRNA expression was calculated using the
comparative CT method.
TRAP Staining
TRAP staining was used to identify osteoclasts in vitro
and in vivo. To examine osteoclast formation in vivo,
the osteoclasts number (N.Oc/B.Pm) was expressed
using the bone perimeter (B.Pm) as a reference. To
examine osteoclast formation in vitro, BMMs were re-
suspended in α-minimum essential medium containing
Table 1 Primer sequences used in this study
Primer name Sequence (5’-3’)
RANK Forward GTC TGC AGC TCT TCC CTG AC
Reverse GAG GAG CAG GAC GAT GAG AC
RANKL Forward ACC AGC ATC AAA ATC CCA AG
Reverse TTT GAA AGC CCC AAA GTA CG
OPG Forward GTT CTT GCA CAG CTT CAC CA
Reverse AAA CAG CCC AGT GAC CAT TC
GAPDH Forward ACC CTA AGG CCA ACC GTG AAA AG
Reverse CAT GAG GTA GTC TGT CAG GT
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(100 ng/ml, PeproTech) and/or ABE (0.16, 0.8, 4 μg/ml,
respectively) in 96 well culture plates (Corning, MA,
USA). Six days later, cells were fixed and stained by
TRAP staining kit (Sigma Alrich, USA) according to the
manufacturer’s protocol. The images were taken with a
digital camera attached to the microscope. TRAP posi-
tive multinucleated cells (>3 nuclei) were scored as
osteoclast-like cells. The number of TRAP-positive cells
was counted using an eyepiece graticule at a magnification
of 100 and the results expressed as the number of cells
per cm2.Cell viability assay
BMM cells were seeded in 96-well plates and incubated
cultured in the presence of M-CSF and RANKL with or
without different concentrations of ABE (0.16, 0.8, 4 μg/ml,
respectively) for 24 h. BMSCs were cultured with or with-
out different concentrations of ABE (0.16, 0.8, 4 μg/ml, re-
spectively) for 24 h. After drug treatment, cells were
washed twice with phosphate-buffered saline (PBS;
pH 7.4), and then cell viability was determined by 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) method using Cell Titer 96® Non-Radioactive Cell
Proliferation Assay (Promega, Madison, USA) according
to the manufacturer’s instructions. All absorbance at
570 nm were measured with a microplate reader.Statistical analysis
SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA)
and SAS version 9.1 software (SAS Institute, Cary, NC,
USA) were used for statistical analysis. All experiments were
performed in triplicate. Continuous variables were expressed
as mean ± standard deviation. For comparisons of means
among multiple groups, one-way ANOVAs followed by
LSD tests were performed. Differences were considered sta-
tistically significant when P <0.05.Results
ABE treatment reduces histopathological changes in rats
with steroid-induced ONFH
To evaluate the effect of ABE treatment on steroid-induced
ONFH, the osteonecrotic changes and repair processes of
rats in each group were histopathologically observed. Com-
pared with the control group, there was an accumulation of
bone marrow cell debris found in ONFH lesions in the
model group, while ABE treatment dramatically attenuated
this change in rats with steroid-induced ONFH (Figure 2A).
In addition, the ratio of empty lacunae in the bone trabecu-
lae of the model group was significantly greater than that of
the control group (P <0.01, Figure 2A and B), and was de-
creased by ABE treatment in a dose-dependent manner
(Figure 2B). Moreover, the adipose tissue area and adipo-
cyte perimeter in the bone marrow, which were dramatic-
ally increased in rats with steroid-induced ONFH, were
dose-dependently reduced by ABE treatment (Figure 2B).
ABE treatment improves the microstructure of the
trabecular bone and increases bone mineral density
(BMD) in rats with steroid-induced ONFH
As shown in Figure 3A–G, the bone volume/tissue
volume (BV/TV, P <0.01), trabecular thickness (Tb.Th,
P <0.01), trabecular bone pattern factor (Tb.Pf ), and
trabecular number (Tb.N, P <0.01) were significantly re-
duced, while the trabecular separation (Tb.Sp, P <0.01)
and structure model index (SMI, P <0.01) were signifi-
cantly increased in rats with steroid-induced ONFH
when compared with controls. ABE treatment protected
rats from steroid-induced effects on the levels of the
above microstructural parameters (Figure 3A–G).
To determine whether ABE treatment increases the bone
mass of rats with steroid-induced ONFH, BMD values were
measured. As shown in Figure 3H, the rats with steroid-
induced ONFH showed markedly reduced BMD in the
femoral head compared with the control rats (P <0.01). The
BMD values in the rats treated with 10.0–22.5 g/kg ABE
were increased in a dose-dependent manner compared to
those without drug treatment (P <0.01).
ABE treatment enhances femoral head neovascularization
in rats with steroid-induced ONFH
The blood vessel microarchitecture of each group was
reconstructed in 3 dimensions for presentation. Com-
pared with the control, both the number and the thick-
ness of vessels in necrotic lesions of the femoral head of
rats with steroid-induced ONFH were markedly reduced,
and vasculatures were not visible, while the samples in
the ABE 10 g/kg group showed some capillary vessels,
and the samples in the ABE 15–22.5 g/kg groups
showed intensive vascular architecture (Figure 4A).
Quantitatively, Figure 4B showed that ABE treatment
dose-dependently increased vessel thickness, percent of
Figure 2 ABE treatment enhances osteogenesis and reverses bone marrow adipogenesis. (A) Histological features of normal bone from a
normal rat, and osteonecrotic bone from rats with steroid-induced ONFH with or without ABE treatment. (B) Statistical analysis of the differences
of the ratio of empty lacuna, adipose tissue area, and adipocyte perimeter in the control, model, ABE 10 g/kg, ABE 15 g/kg, and ABE 22.5 g/kg
groups. Data are presented as the mean ± S.D. (n =20 for control, n =25 for model group, n =20 for ABE treatment groups). ##: P <0.01, in
comparison with the control group. * and **: P <0.05 and P <0.01, respectively, in comparison with the model group. The arrow heads indicate
necrosis area.
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femoral heads of rats with steroid-induced ONFH.
ABE treatment improves hyperlipidemia in rats with
steroid-induced ONFH
Blood chemistry data showed that steroid hormone admin-
istration (model group) induced marked hyperlipidemia.
Steroid administration significantly elevated TG (Figure 5B),
TC (Figure 5A), LDL (Figure 5C), ApoA1 (Figure 5E) and
ApoB (Figure 5F) levels, but significantly decreased HDL
levels (Figure 5D). Administration of 10–22.5 g/kg ABE
dose-dependently improved hyperlipidemia by decreasing
TG (P <0.01, Figure 5B), TC (P <0.01, Figure 5A), LDL
(P <0.05, Figure 5C), ApoA1 (P <0.05, Figure 5E), and
ApoB (P <0.05, Figure 5F) levels, and increasing HDL
levels (P <0.05, Figure 5D).
ABE treatment inhibits osteoclast differentiation and
activates bone formation markers in rats with steroid-
induced ONFH
To confirm the effect of ABE on the number of osteoclasts,
the femoral head sections were stained with TRAP. Only
TRAP-positive multinucleated cells located at the bone sur-
face within the bone destruction were considered to be oste-
oclasts (Figure 6A). Compared with steroid-induced ONFH
model rats, the numbers of osteoclasts in the areas of bone
destruction were significantly decreased in ABE-treated rats
with a tendency for dose-dependence (P <0.01, Figure 6B).In line with histological observations, serum TRAP activ-
ity level was significantly increased in rats with steroid-
induced ONFH compared to control rats (0.77 ± 0.34 U/L
vs. 2.57 ± 1.13 U/L, P <0.01, Figure 6C). After ABE treat-
ment, serum TRAP activity levels were severely reduced in
a dose-dependent manner (Figure 6C). In contrast, serum
BAP activity levels decreased to 55.07 ± 21.43 U/L in rats
with steroid-induced ONFH, which were significantly lower
than control rat levels (90.38 ± 34.12 U/L, P <0.01,
Figure 6D). After the ABE treatment, the serum BAP activ-
ity level was markedly increased in a dose-dependent man-
ner (Figure 6D).
ABE treatment regulates RANKL/RANK/OPG signaling
in rats with steroid-induced ONFH
We detected changes in RANKL, RANK, and OPG expres-
sion at mRNA and protein levels in the sera and femoral
heads of rats with steroid-induced ONFH with or without
ABE treatment. As shown in Figure 7A, serum RANK and
RANKL levels in rats with steroid-induced ONFH were sig-
nificantly higher than levels in control rats (RANK: 60.32 ±
19.52 U/L vs. 23.33 ± 4.26 U/L, P <0.01; RANKL: 63.33 ±
13.24 U/L vs. 35.74 ± 9.41 U/L, P <0.01). In contrast, serum
OPG levels were significantly decreased in rats with steroid-
induced ONFH compared with control rats (28.50 ± 10.19
U/L vs. 60.68 ± 19.67 U/L, P <0.01, Figure 7A). After ABE
treatment, serum RANK and RANKL levels were dose-
dependently reduced, while serum OPG levels were dose-
Figure 3 ABE treatment improves the microstructure of the femoral head. (A) and (B) refer to two-dimensional (2D) and three-dimensional
(3D) pictures, respectively, of normal bone from normal rats, and osteonecrotic bone in rats with steroid-induced ONFH with or without ABE
treatment. Statistical analysis was performed on the differences in BV/TV (C), Tb.Pf (D), Tb.Th (E), Tb.N (F), Tb.sp (G), and BMD (H) in the control,
model, ABE 10 g/kg, ABE 15 g/kg and ABE 22.5 g/kg groups. Data are presented as the mean ± S.D. (n =20 for control, n =25 for model, n =20 for
ABE 10 g/kg, ABE 15 g/kg and 22.5 g/kg). # and ##: P <0.05 and P <0.01, respectively, in comparison with the control group. * and **: P <0.05
and P <0.01, respectively, in comparison with the model group.
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ment significantly reduced transcript abundance of RANKL
and RANK, but increased abundance of OPG, in the fem-
oral heads of rats with steroid-induced ONFH (P <0.05,
Figure 7B).
In accordance with quantitative real-time RT-PCR results,
changes in RANKL, RANK, and OPG protein expression
were reversed by 10–22.5 g/kg ABE in a dose-dependent
manner (P <0.01, Figure 7C). Furthermore, ABE markedlyreduced the ratio of RANKL to OPG in the sera and femoral
heads of rats with steroid-induced ONFH in a dose-
dependent manner (P <0.01, Figure 7D).
ABE treatment inhibits RANKL-induced osteoclast
differentiation in BMMs
When BMMs were incubated with M-CSF and RANKL
for 6 days, numerous TRAP-positive multi-nucleated
osteoclasts were generated (Figure 8A). Addition of
Figure 4 ABE treatment enhances femoral head neovascularization. (A) Representative images of micro-CT reconstructed 3-D microangiography
of proximal femur from control, model, ABE 10 g/kg, ABE 15 g/kg, and ABE 22.5 g/kg groups. (B) Statistical analysis was performed on differences in
vessel thickness, percentage of vessel volume, vessel volume, and vessel surface in the femoral heads of rats with steroid-induced ONFH. Data are
presented as the mean ± S.D. (n =10). # and ##: P <0.05 and P <0.01, respectively, in comparison with the control group. * and **: P <0.05 and P <0.01,
respectively, in comparison with the model group.
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dependent inhibition of osteoclast formation as measured
by the TRAP positive multinucleated cells (Figure 8A and
B). Notably, osteoclast-like cells in cultures that were
treated with ABE exhibited morphological differences from
model osteoclast-like cells, containing fewer numbers
of nuclei compared to osteoclast-like cells in model
(Figure 8C). ABE without the presence of RANKL did not
stimulate osteoclast development (data not shown).
ABE treatment regulates the expression of RANKL and
OPG in BMSCs
Compared with model group, doses of 0.16 ~ 4 μg/ml
ABE significantly reduced the expression of RANKL,
and enhanced the expression of OPG in supernatant of
BMSCs with a dose-related manner (Figure 9). More
interestingly, ABE treatments markedly decreased the
ratio of RANKL to OPG. MTT assay also showed that
the anti-osteoclastogenic effect of ABE was not attribut-
able to cellular toxicity (Figure 10).
Discussion
Excessive steroid treatment induces bone microstructure
integrity loss that leads to femoral head collapse and
osteoarthritis, and eventually to the need for total hip re-
placement [20]. Due to the uncertain pathophysiology ofsteroid-induced ONFH, the best approach to prevent the
progression of this disease remains unknown. A large
number of kidney-tonifying agents have been used in
TCM to treat bone diseases for thousands of years.
Among them, ABE has been demonstrated to prevent
bone loss [21]. However, its potential role in the treat-
ment of steroid-induced ONFH remains unknown. In
the current study, the main findings were: 1) ABE atten-
uated steroid-induced ONFH by reducing osteonecrotic
changes and bone marrow adipogenesis; 2) ABE im-
proved the microstructure of the trabecular bone and
increased BMD in the femoral head of rats with steroid-
induced ONFH; 3) ABE enhanced femoral head neovas-
cularization and improved the hyperlipidemic state of
rats with steroid-induced ONFH; 4) ABE inhibited
osteoclast differentiation and improved bone formation
by regulating RANKL/RANK/OPG signaling in rats with
steroid-induced ONFH; 5) ABE inhibited RANKL-
induced osteoclast differentiation in BMMs and regu-
lated the expression of RANKL and OPG in BMSCs.
Achyranthes bidentata is an annual herb that is found
in hilly districts of China, Korea, Japan, and India, and
widely applied in traditional medicine [7]. This plant
produces expectorant, anti-inflammatory, antipyretic,
antirheumatic, and diuretic effects, and is commonly
prescribed for the treatment of spasm, osteodynia of the
Figure 6 ABE inhibits osteoclast differentiation in rats with steroid-induced ONFH. (A) Tartrate-resistant acid phosphatase (TRAP) stained
sections from the femoral head of control, model, and ABE-treated rats. (B) The number of osteoclasts (multinucleated TRAP-positive cells) in the
femoral head of control, model, and ABE-treated rats. (C) Serum TRAP activity in the serum of control, model, and ABE-treated rats. (D) Serum
BAP activity in the serum of control, model, and ABE-treated rats. Data are presented as the mean ± S.D. (n =20 for control, n =25 for model,
n =20 for ABE 10 g/kg, ABE 15 g/kg, and 22.5 g/kg groups). # and ##: P <0.05 and P <0.01, respectively, in comparison with the control group.
* and **: P <0.05 and P <0.01, respectively, in comparison with the model group. The arrow heads indicate osteoclasts.
Figure 5 ABE treatment improves hyperlipidemia in rats with steroid-induced ONFH. Steroid hormone administration (the model group)
induced marked hyperlipidemia, as indicated by significantly elevated TC (A), TG (B), LDL (C), ApoA1 (E), and ApoB (F) levels, but significantly
decreased HDL levels (D). Doses of 10–22.5 g/kg ABE significantly reduced hyperlipidemia by decreasing TC (A), TG (B), LDL (C), ApoA1 (E), and
ApoB (F) levels, and increasing HDL levels (D). Data are presented as the mean ± S.D. (n =20 for control, n =25 for model, n =20 for ABE 10 g/kg,
ABE 15 g/kg, and 22.5 g/kg groups). # and ##: P <0.05 and P <0.01, respectively, in comparison with the control group. * and **: P <0.05 and P
<0.01, respectively, in comparison with the model group.
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Figure 7 ABE treatment regulates the RANKL/RANK/OPG signaling pathway in rats with steroid-induced ONFH. RANK, RANKL, and OPG levels
in the serum of rats with steroid-induced ONFH with or without ABE treatment were detected by ELISA (A). RANKL, RANK, and OPG expression in the
femoral heads of rats with steroid-induced ONFH with or without ABE treatment were detected at mRNA and protein levels by quantitative real-time
RT-PCR (B), western blot (C), respectively. (D) shows the ratio of RANKL/OPG in the serum, the ratio of RANKL mRNA/OPG mRNA, and the ratio of RANK
protein/OPG protein in the rats with steroid-induced ONFH with and without ABE treatment. Data are presented as the mean ± S.D. (n =20 for control,
n =25 for model, n =20 for ABE treatment groups). ##: P <0.01, in comparison with the control group. * and **: P <0.05 and P <0.01, respectively, in
comparison with the model group.
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regard to bone diseases, in 2010 He et al. [23] reported that
the n-butanol-soluble fraction of Achyranthes bidentata
root prevented bone loss in ovariectomized rats and may
have potential as an alternative treatment for osteoporosis.
In 2012, Zhang et al. [21] reported that ABE treatment im-
proved biomechanical bone quality through modification of
BMD and trabecular microarchitecture without hyperplas-
tic effects on the uterus, therefore ABE might be a potential
alternative treatment for postmenopausal osteoporosis.
The current study was designed to systematically evalu-
ate the therapeutic effects of ABE on steroid-inducedONFH in rats. During histopathological examination, we
found that lesions in rats with steroid-induced ONFH
showed empty lacunae accompanied by surrounding mar-
row cell necrosis and occupation of adipocytes, which are
primary features of the early stage of this disease. After
ABE treatment, the ratio of empty lacunae and the area of
bone marrow occupied by adipocytes were significantly
reduced, suggesting that improvement in local lipid me-
tabolism was induced by ABE. In addition, the ABE treat-
ment increased bone formation in the femoral head, and
these changes were associated with higher bone volume
(BV/TV) and trabecular number (TbN). Moreover, ABE
Figure 8 ABE inhibits RANKL-induced osteoclastdifferentiation inbone marrow derived macrophages (BMMs). (A) BMMs were cultured in
the presence of M-CSF and RANKL withor without different concentrations of ABE (0.16, 0.8, 4 μg/ml, respectively). Six days post-culture, cells were
fixed with 4% paraformadehyde followed by TRAP staining. Representative images of TRAP staining of osteoclast-like cells from one of the three
experiments are shown. B-C: Quantitative analysis show the mean number of TRAP-positive osteoclast-like cells (B), mean osteoclast-like cells
nuclei numbers (C). Data are represented as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 significantly
different from Model group.
Jiang et al. Journal of Translational Medicine 2014, 12:334 Page 11 of 13
http://www.translational-medicine.com/content/12/1/334improved the trabecular microarchitecture, in part by re-
storing trabecular connectivity through increasing trabecu-
lar thickness (TbTh), while reducing trabecular separation
(TbSp), which is consistent with the increase in BMD.
These results suggest that ABE could prevent the loss of
bone mass induced by excessive steroid treatment.
Because impeded blood flow through the femoral head is
implicated in the pathogenesis of steroid-induced ONFH,
we applied a novel Micro-CT-based micro-angiography
technique to visualize and quantify new blood vessel forma-
tion and vascularization in the femoral head of the rat.Figure 9 ABE regulates the expression of RANKL and OPG in bone m
or without different concentrations of ABE (0.16, 0.8, 4 μg/ml, respectively).
amounts of RANKL (A) and OPG (B) in the supernatants by ELISA. (C) refers
as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01 aRecent studies have demonstrated that this technique is
quantitative and effective for assessing vascularization
[17,18]. Consistent with the improvement produced by ABE
treatment on the microstructure of the trabecular bone and
BMD, we observed a significant increase in blood vessel
volume, vessel surface, percentage of vessel volume, and ves-
sel thickness in the ABE-treated groups, suggesting a dose-
dependent increase in vascularization of the femoral heads
in this rat model. These findings imply that ABE treatment
may produce an environment conducive to bone formation
by generating a blood supply for bone reconstruction.arrow mesenchymal stem cells (BMSCs). BMSCs were cultured with
Three days post-culture, supernatants were obtained to detectthe
to the ratio of RANKL/OPG in the supernatants. Data are represented
nd ***P < 0.001 significantly different from Model group.
Figure 10 ABE has no effect on the cell viabilities of bone marrow derived macrophages (BMMs) and bone marrow mesenchymal stem
cells (BMSCs). (A) BMMs were cultured in the presence of M-CSF and RANKL with or without different concentrations of ABE (0.16, 0.8, 4 μg/ml,
respectively). (B) BMSCs were cultured with or without different concentrations of ABE (0.16, 0.8, 4 μg/ml, respectively). Twenty-four hours later,
cells were determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. Cell viability of the control was taken as 100%.
Data are represented as the mean ± SD of three independent experiments.
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dynamic balance between bone formation by osteoblasts
and bone resorption by osteoclasts [24]. The main cause of
steroid-induced ONFH is excessive bone resorption that
exceeds the rate of bone formation, leading to loss of bone
mass. In this context, we observed the effects of ABE treat-
ment on the number of osteoclasts, as well as its regulatory
effects on TRAP and BAP, which are markers of osteo-
blastic bone formation and osteoclastic bone resorption, re-
spectively. Our data showed that ABE treatment reduced
numbers of osteoclasts and suppressed serum TRAP, but
increased serum BAP, implying that ABE may inhibit osteo-
clastogenesis while promoting osteoblastogenesis in rats
with steroid-induced ONFH.
Accumulating studies have indicated that osteoclast-
mediated bone destruction is regulated by the RANKL/
RANK/OPG signaling pathway [25,26]. RANK and its lig-
and RANKL are crucial regulators of osteoclast differenti-
ation. Under physiological conditions, RANKL is expressed
in osteoblasts and activated T cells [27], and triggers osteo-
clast maturation and bone resorption by binding with
RANK on osteoclasts. As a soluble decoy receptor for
RANKL, OPG is expressed by osteoblasts and inhibits bone
resorption by binding with RANKL, which prevents RANKL
binding to RANK [28]. Under pathological conditions, the
RANKL/RANK/OPG signaling pathway plays a crucial role
in the process of bone destruction [29,30]. Bone resorption
is regulated locally by the balance between RANKL and
OPG. In the current study, we observed down-regulation of
OPG, up-regulation of RANK and RANKL, and an in-
creased ratio of RANKL to OPG in the sera and the necrotic
femoral head, which were reversed by ABE treatment. Since
RANKL is essential and sufficient for the differentiation of
osteoclast precursors into mature osteoclasts in the presence
of M-CSF [31,32], our data confirmed the inhibitive effects
of ABE on RANKL-induced osteoclast formation from
BMMs. Moreover, BMSCs and BMMs are originated frombone marrow, and RANKL and OPG expression in BMSCs
can regulate osteoclast development and function [33,34].
To clarify the anti-osteoclastogenicaction mechanism of
ABE, the RANKL and OPG protein expression levels de-
rived from BMSCs were further detected. As a result, our
data showed that ABE treatment could reduce RANKL ex-
pression and enhance OPG expression in BMSCs. Thus,
both in vivo and in vitro evidence suggest the regulatory ef-
fects of ABE treatment on the RANKL/RANK/OPG signal-
ing pathway, which has been considered as a potential target
for the prevention of bone destruction in steroid-induced
ONFH patients.
In conclusion, our data offer for the first time
evidence that ABE prevents steroid-induced ONFH and
alleviates steroid-induced bone deterioration by regulat-
ing the RANKL/RANK/OPG signaling pathway. Thus,
ABE should be considered a potential candidate drug
for the treatment of steroid-induced ONFH.
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